Skip to main content
Clinical Trials/CTIS2023-509575-16-00
CTIS2023-509575-16-00
Active, not recruiting
Phase 1

ow-Intervention Clinical Trial Evaluating a Novel Cytokine Release Assay for Tick-Borne Encephalitis (TBE) Among Healthy and Immunosuppressed Research Participants - 2023-509575-16-00

Vaestra Goetalandsregionen0 sites100 target enrollmentFebruary 12, 2024

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Tick-borne encephalitis
Sponsor
Vaestra Goetalandsregionen
Enrollment
100
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 12, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Vaestra Goetalandsregionen

Eligibility Criteria

Inclusion Criteria

  • The subject has given their written consent to participate in the clinical trial., Male and female research participants above or equal to 18 years of age.

Exclusion Criteria

  • Women with ongoing pregnancy or breast feeding without prior history of hospitalization for TBE or vaccination against TBEV., Inability or unwillingness to provide informed consent or abide by the requirements of the clinical trial., Evidence of allergy or other known adverse reaction to components are part of the TBE vaccine (FSME\-IMMUN Vuxen) for unvaccinated participants planning to undergo vaccination against TBEV in the clinical trial., Having a bleeding disorder or receiving preventive anticoagulation therapy which prevents the vaccine being administered intramuscularly, for individuals without prior history of hospitalization for TBE or prior vaccination against TBEV.

Outcomes

Primary Outcomes

Not specified

Similar Trials